| Mast-cell derived nerve growth factor drives ILC2 pro-tumoral functions in bladder cancer | Nature communications |  | | 2026 | 64 | 42 |
|
| Randomized double-blind clinical study in patients with COVID-19 to evaluate the safety and efficacy of a phytomedicine (P2Et) | Frontiers in medicine | | | 2022 | 242 | 141 |
|
| c-Maf enforces cytokine production and promotes memory-like responses in mouse and human type 2 innate lymphoid cells | EMBO journal | | | 2022 | 387 | 553 |
|
| PPARɣ drives IL-33-dependent ILC2 pro-tumoral functions | Nature Communications | | | 2021 | 361 | 317 |
|
| Severe COVID-19 patients exhibit an ILC2 NKG2D+ population in their impaired ILC compartment | Cellular & Molecular Immunology | | | 2021 | 249 | 149 |
|
| Immune system activation by natural products and complex fractions: a network pharmacology approach in cancer treatment | Cell Stress | | | 2020 | 344 | 234 |
|
| Immunosuppressive mediators impair proinflammatory innate lymphoid cell function in human malignant melanoma | Cancer Immunology Research |  | | 2020 | 640 | 4 |
|
| Immunophenotyping of human innate lymphoid cells | Methods in Molecular Biology | | | 2019 | 340 | 1 |
|
| Peripheral innate lymphoid cells are increased in first line metastatic colorectal carcinoma patients: a negative correlation with th1 immune responses | Frontiers in Immunology | | | 2019 | 334 | 160 |
|
| CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML | Blood Advances | | | 2019 | 548 | 280 |
|
| Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis | Nature Communications | | | 2017 | 691 | 264 |
|
